Bowel perforation during initial treatment for childhood non-Hodgkin's lymphoma.
In the last 5 years we have seen six cases of bowel perforation during initial therapy for childhood non-Hodgkin's lymphoma (NHL). Perforation occurred only in patients with Stage III or IV disease. It occurred in patients without clinically detectable mural disease of bowel. Children who suffered bowel perforation had a worse outcome than those who did not, but two of the six patients described have gone on to long-term disease-free survival more than 2 years from completion of their treatment.
D000008:Abdominal Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D000293:Adolescent; D002648:Child; D003131:Combined Modality Therapy; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007077:Ileal Diseases / Q000209:etiology / Q000473:pathology*; D007416:Intestinal Perforation / Q000209:etiology / Q000473:pathology*; D007813:Laparotomy; D008223:Lymphoma / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D010534:Peritoneal Neoplasms / Q000628:therapy; D012086:Reoperation; D012186:Retroperitoneal Neoplasms / Q000628:therapy
D003630:Daunorubicin